JCJulie Charles

Julie Charles

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Julie Charles has a total of 704 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Metabolic Profiling of Circulating and Tumour‐Infiltrating T Cells Uncovers Bioenergetic Checkpoints Linked With Immune and Clinical Skewing in Melanoma Patients

    by Hugo Brouque, Kareem Mahdy, Stephane Mouret, Sylvain Henry, Camille Niveau, Mélanie Cettour‐Cave, Martin Pelosse, Florence de Fraipont, Julie Charles, Andrei Turtoi, et al.

    Metabolism is critical for immune cell functions. Tumours shape their microenvironment to render it metabolically hostile for infiltrating immune cells. While targeting immunometabolism emerges as a promising way to reinvigorate anticancer immunity, a deeper understanding of the metabolic disturbances of immune cells is needed. Here, we explored how the metabolic status of T cells governs immune skewing from circulating and tumour‐infiltrating CD4 + and CD8 + T cells of melanoma patients at a single‐cell level using the SCENITH method and targeted metabolomics. Circulating and tumour‐infiltrating T cells from patients displayed a decreased mitochondrial dependency associated with an enhanced glycolytic capacity and a skewed metabolic reprogramming upon stimulation. Such metabolic disturbances were linked to the activation status, immune checkpoint profile and functional orientation of T cells, underlining critical connections between T‐cell features and metabolic patterns. Targeted metabolomics within sorted CD4 + /CD8 + T cells identified a decrease in citrulline, cysteine and threonine within all subsets in patients, together with a sharp rise in sterol cholesterol CE(20:2) and ceramide dhCer(d18:0/22:0) within tumour‐infiltrating CD4 + T cells, and in glycerolipid DG(16:0/16:0) within CD8 + T cells in blood and tumour. We further outlined a metabolic‐checkpoint‐based signature composed of six genes coding enzymes/transporters connected to the imbalanced metabolites found within tumour‐infiltrating T cells ( LIPA , DGKA , GLUL , SLC38A1 , SLC7A7 , GCH1 ) that shape patients' clinical outcome. These findings outline the skewed bioenergetic profiles of T cells and depict metabolic checkpoints associated with immune subversion. Harnessing metabolic pathways is promising for developing innovative therapies to restore optimal anti‐tumour responses and improve clinical success.

  • Survival outcomes of adjuvant therapy in resected stage III melanoma: results from a real-life cohort study (TAMARIS)

    by Théo Erard, Gaelle Quéreux, Mona Amini-Adle, Henri Montaudié, Julie Charles, Marc Puyraveau, Géraldine Jeudy, Philippe Bernard, Florent Grange, Delphine Legoupil, et al.


  • Serum IGF1 Is a Prognostic Marker for Resistance to Targeted Therapies and a Predictive Marker for Anti-IGF1 Receptor Therapy in Melanoma

    by Camila Castillo-Ferrer, Théo Marguet, Laetitia Vanwonterghem, Sule Erbek, Florent Chuffart, Stéphane Mouret, Sabiha Trabelsi Messai, Anne-Sophie Gauchez, Jean-Luc Coll, Julie Charles, et al.


  • Immunothérapie dans le mélanome en hospitalisation à domicile : enquête de satisfaction et retour d’expérience des centres français d’oncodermatologie

    by Thao Truong, Marie Lapassat, Marie-Thérèse Leccia, Juliana Costa, Stéphane Mouret, Laurence Bouillet, Aude Lemoigne, Julie Charles, Sabiha Trabelsi


  • Natural History of Perianal Fistulising Lesions in Patients With Elderly-onset Crohn’s Disease: A Population-based Study

    by Marie Danielou, Hélène Sarter, Benjamin Pariente, Mathurin Fumery, Delphine Ley, Christel Mamona, Maël Barthoulot, Cloé Charpentier, Laurent Siproudhis, Guillaume Savoye, et al.

    Introduction: Most studies of elderly-onset Crohn’s disease [CD; diagnosed in patients aged 60 or over] have described a mild course. However, data on the natural history of perianal fistulising CD [pfCD] in this population are scarce. In a population-based cohort study, we described the prevalence, natural history, and treatment of pfCD in patients with elderly-onset CD vs patients with paediatric-onset CD. Method: All patients diagnosed with CD at or after the age of 60 between 1988 and 2006, were included [n = 372]. Logistic regression, Cox models, and a nested case-control method were used to identify factors associated with pfCD. Results: A total of 34 elderly patients [9% of the 372] had pfCD at diagnosis. After a median follow-up of 6 years (interquartile range [IQR]: 3; 10), 59 patients [16%] had pfCD; the same prevalence [16%] was observed in paediatric-onset patients. At last follow-up, anal incontinence was more frequent in elderly patients with pfCD than in elderly patients without pfCD [22% vs 4%, respectively; p < 10–4]. Rectal CD at diagnosis was associated with pfCD: hazard ratio (95% confidence interval [CI] = 2.8 [1.6–5.0]). Although 37% of the patients received immunosuppressants and 17% received anti-tumour necrosis factor agents, 24% [14 out of 59] had a definitive stoma at last follow-up. Conclusion: During the first 6 years of disease, the prevalence of pfCD was similar in elderly and paediatric patients. Rectal involvement was associated with the appearance of pfCD in elderly-onset patients. Around a quarter of patients with elderly-onset CD will have a stoma. Our results suggest that treatment with biologics should be evaluated in these patients.


  • Open Access

    Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation

    by Julie Charles, Diane Giovannini, Nicolas Terzi, Carole Schwebel, Nathalie Sturm, Dominique Masson, Marie-Thérèse Leccia, Jean-Yves Cahn, Olivier Manches, Claude-Eric Bulabois, et al.

    Immune checkpoint inhibitors have radically changed the landscape of anti-tumor therapies in several malignancies. However the adverse events associated with immune checkpoint blockade in combination with other treatments remains to be thoroughly documented. Here we report the case of a 33-year-old male with classical Hodgkin lymphoma who was successfully treated for lymphoma but experienced serious and eventually fatal multisystem organ failure following nivolumab administration and allogeneic stem cell transplantation. The patient was diagnosed with stage IIIa nodular sclerosing Hodgkin lymphoma. Originally treated by chemotherapy and autologous stem cell transplantation, he subsequently received two allogeneic stem cell transplants from matched and haplo-identical siblings upon successive disease recurrences. Nivolumab treatment was administered prior to the second allograft, after which complete remission of lymphoma was achieved (year 10), as evidenced by clinical and radiographic examination. However within the next 3 months, the patient went on to develop a constellation of symptoms affecting multiple organs, including acute pneumonia with no evidence of bacterial infection, widespread cutaneous eruptions on trunk and lower limbs, mucosal ulcerations, myositis, diarrhea and colitis. Further complications included hepatic cytolysis, acute renal failure, pancreatitis, as well as complete heart block. Some of these injuries being suggestive of graft-versus-host disease, the patient was administered immunosuppressive therapy (mycophenolate, steroids and polyvalent immunoglobulins), but died shortly afterwards. Tissue biopsies revealed extensive lymphocytic infiltration (mostly CD3 + T cells) in skin, liver, and most peculiarly in muscles, including the myocardium. Massive lymphoid-histiocytic infiltration of muscle fibers was accompanied by acute necrotizing myositis and endomysial inflammation. Multi-organ failure represents a rare but potentially fatal outcome of immune checkpoint blockade in patients receiving allogeneic stem cell grafts. Nivolumab may induce atypical immune-mediated tissue inflammation and damage, such as the extensive muscular polymyositis described here in a patient with Hodgkin lymphoma. Nivolumab might also worsen GVHD symptoms in the context of allogeneic stem cell transplantation. Irrespective of the actual pathological mechanisms, clinicians should be alerted to these fatal drug-related toxicities.


  • Open Access

    Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy

    by Paolo A. Ascierto, Georgina V. Long, Caroline Robert, Benjamin Brady, Caroline Dutriaux, Anna Maria Di Giacomo, Laurent Mortier, Jessica C. Hassel, Piotr Rutkowski, Catriona McNeil, et al.

    The programmed cell death 1 (PD-1) receptor inhibitors nivolumab and pembrolizumab have demonstrated superior efficacy compared with chemotherapy or the cytotoxic T-lymphocyte–associated antigen 4 inhibitor ipilimumab in advanced melanoma, with a lower incidence of treatment-related grade 3/4 adverse events (AEs).1-6 In phase 2 and phase 3 trials, the combination of nivolumab and ipilimumab has demonstrated significantly longer progression-free survival and a higher objective response rate compared with ipilimumab alone.1,7-9


  • Fixed drug eruption caused by fulvestrant confirmed by skin tests: First case

    by Clémentine Broche, Pauline Pralong, Hugo Gil, Nassima Yahiaoui, Mireille Mousseau, Catharina Chatain, Jean‐Pierre Jacquier, Julie Charles, Marie‐Thérèse Leccia